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Abstract
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) ligand family that exerts its
apoptotic activity in human cells by binding to two transmembrane receptors, TRAILR1 and TRAILR2. In cells co-expressing
both receptors the particular contribution of either protein to the overall cellular response is not well defined. Here we have
investigated whether differences in the signaling capacities of TRAILR1 and TRAILR2 can be attributed to certain functional
molecular subdomains. We generated and characterized various chimeric receptors comprising TRAIL receptor domains
fused with parts from other members of the TNF death receptor family. This allowed us to compare the contribution of
particular domains of the two TRAIL receptors to the overall apoptotic response and to identify elements that regulate
apoptotic signaling. Our results show that the TRAIL receptor death domains are weak apoptosis inducers compared to
those of CD95/Fas, because TRAILR-derived constructs containing the CD95/Fas death domain possessed strongly
enhanced apoptotic capabilities. Importantly, major differences in the signaling strengths of the two TRAIL receptors were
linked to their transmembrane domains in combination with the adjacent extracellular stalk regions. This was evident from
receptor chimeras comprising the extracellular part of TNFR1 and the intracellular signaling part of CD95/Fas. Both receptor
chimeras showed comparable ligand binding affinities and internalization kinetics. However, the respective TRAILR2-derived
molecule more efficiently induced apoptosis. It also activated caspase-8 and caspase-3 more strongly and more quickly,
albeit being expressed at lower levels. These results suggest that the transmembrane domains together with their adjacent
stalk regions can play a major role in control of death receptor activation thereby contributing to cell type specific
differences in TRAILR1 and TRAILR2 signaling.
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Introduction
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the tumor necrosis factor (TNF) ligand
family, exerting its bioactivity on human cells via binding to five
partners, comprising the soluble molecule osteoprotegerin (OPG)
and four cell surface receptors in the human system [1]. Two of
the receptors, TRAILR1 (also called DR4, APO-2 or
TNFRSF10A) and TRAILR2 (DR5, TRICK2 or TNFRSF10B),
are capable to activate a prominent form of programmed cell
death, termed apoptosis, through their cytoplasmic death domains
(DD). Two other receptors, TRAILR3 (DcR1, TRID, LIT) and
TRAILR4 (DcR2, TRUNDD) may serve as decoy receptors by
competitive ligand binding and/or the formation of mixed and
thus non-functional ligand/receptor complexes [2]. TRAILR3 is a
GPI-anchored molecule, therefore possessing no intracellular
signaling domain at all, and TRAILR4 features a truncated death
domain with sparsely defined signaling capabilities. OPG binds
TRAIL with low affinity with unclear biological impact of this
interaction [3]. To date, current research on the TRAIL system
focuses on cellular responses mediated through TRAILR1 and
TRAILR2. Most normal tissues are resistant to the apoptotic
action of TRAIL despite cell surface receptor expression, whereas
several cancer cells show remarkable sensitivity to it [4].
Therefore, TRAIL or other TRAIL receptor agonists are
currently being investigated as candidates for therapeutic inter-
vention especially for cancer treatment [5,6].
Like most members of the TNF receptor family both apoptosis-
inducing TRAIL receptors show the typical topology of many type
I proteins. The extracellular C-terminal part contains three
cysteine-rich domains (CRD). These CRDs form the ligand
interaction site and a homophilic interaction domain at the
membrane-distal region, called pre-ligand binding assembly
domain (PLAD) [7]. Interestingly, and in contrast to e.g. the
TNF system [8], PLAD-mediated interactions of membrane-
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expressed TRAILR allow homo- as well as heteromer formation,
strengthening the arguments for TRAILR3 and TRAILR4 to play
a role as inhibitory molecules. The respective membrane proximal
CRDs are linked via so-called stalk regions to their transmem-
brane domains (TM). The intracellular parts contain the DD
capable of binding additional DD-affine adapter proteins such as
FADD (Fas associated death domain protein) [9]. Apoptotic
signaling is then initiated by recruitment and autoproteolytic
activation of procaspases-8 and/or -10 into the death-inducing
signaling complex (DISC). However, the molecular composition of
the DISC may vary depending on cell type and activation status.
Characteristic of most TNF family members, the ligand TRAIL
is primarily expressed as a type 2 transmembrane protein which
can be processed by proteases to release the soluble form [1]. Both,
membrane-bound TRAIL (memTRAIL) and the soluble molecule
(sTRAIL) form non-covalently linked homotrimers coordinated by
three cysteine residues binding a central zinc ion [10]. Homo-
trimeric TRAIL has the capability to bind up to three receptor
molecules in the grooves between its individual subunits [11]. As
unligated receptors also form homo-oligomers via the PLAD, it is
feasible that ligation of receptors leads to formation of larger
clusters, as proposed for the TNF system recently [12,13].
Many human cells and cell lines co-express TRAIL receptors 1
and 2 which may positively cooperate in apoptosis induction upon
activation by their ligand. Whether and to what extent mixed
receptor complexes contribute to signaling is unknown. In
different cellular systems the overall cellular response might be
dominated by either receptor [14–17]. Most ligand binding affinity
studies demonstrate comparable values for both receptors with
apparent dissociation constants in the low nanomolar range
[18,19], although much higher affinity values have been also
published [20].
The aim of the present study was to investigate whether
differences in the signaling capabilities of TRAILR1 and
TRAILR2 can be attributed to particular domains of these
molecules. For this purpose we have constructed various receptor
chimeras where functional domains of TRAIL receptors had been
exchanged by the corresponding domains from other death
receptors. Analysis of these chimeras demonstrates that the
capacity to activate apoptotic signaling is regulated not only at
the level of binding partner interaction, i.e. ligand binding to the
extracellular part and adapter protein binding to the intracellular
part, but unexpectedly also by the respective transmembrane
domains together with their adjacent stalk regions. These results
suggest that processes of spatial arrangement like recruitment into
particular membrane microdomains and cluster formation co-
regulate sensitivity of TRAIL receptors and in particular the
differential characteristics of TRAILR1 and TRAILR2.
Results
The death domains of TRAIL receptors are weak
apoptosis inducers compared to the CD95/Fas death
domain
In the present work we chose large T antigen-immortalized
embryonic mouse fibroblasts (MF) as cellular model. These cells
are unresponsive to TRAIL-mediated cytotoxic effects even in the
presence of an antibody cross-linking the ligand and/or cyclohex-
imide (CHX) which is an inhibitor of protein synthesis and known
apoptosis-sensitizer (Fig. 1A). In a first approach we compared the
apoptotic signaling capability of the two death domain positive
human TRAIL receptors TRAILR1 and TRAILR2 which were
stably expressed in MF at comparable levels (Fig. 1B and 1C,
insets). No cytotoxic response was observed after stimulation with
TRAIL under various conditions, including the presence of CHX
and/or the use of a ligand-specific antibody to increase the
potency by secondary cross-linking. In addition, no significant
activation of caspase-8 or -3 could be observed within a time frame
of 24 hours (Fig. 1B and 1C). As we have previously shown that
Fas and TNFR-Fas chimeras are rapid and strong apoptosis
inducers in MF (data not shown, [21]), these results demonstrate
that significant differences must exist between signal initiation of
TRAIL receptors and Fas.
We next constructed and characterized TRAILR-Fas chimeras
by replacing the intracellular parts of TRAIL receptors 1 and 2
containing the DD with that of Fas (Fig. 2A). As shown by flow
cytometry these receptor chimeras were expressed in MF at
comparable and high levels (Fig. 2B). We first studied ligand
binding affinities of both TRAILR-Fas chimeras in comparison to
the respective wildtype TRAIL receptors by equilibrium binding
competition studies using radioiodinated TRAIL. Comparable
affinity values were obtained for the respective wild-type and
chimeric receptor pairs by similar displacement rates with non-
labeled TRAIL. Whereas the IC50–value for TRAILR1 (chimera)
was around 17 nM, TRAILR2 (chimera) showed a significantly
higher ligand binding affinity with approximately four-fold lower
IC50-values (representative results are shown in Fig. 2C)
(TRAILR1: IC50=17.764.3 nM, TRAILR1-Fas: IC50=16.8
66.7 nM; TRAILR2: IC50=3.562.8 nM, TRAILR2-Fas: IC50
=5.561.8 nM; mean values 6 SD, n= 3). These data indicate
that the exchange of the intracellular signaling parts had not
affected ligand/receptor interaction. The obtained IC50-values in
the lower nanomolar range are in accordance with dissociation
constant values from literature data [18,19] and overlap with the
concentration range of 100–800 ng/ml of TRAIL used in our
experimental studies.
In contrast to the respective wild-type TRAIL receptors, both
TRAILR-Fas chimeras were capable to induce strong cytotoxic
responses. In MF positive for TRAILR1-Fas (MF-TRAILR1-Fas
cells) the presence of CHX was necessary to allow a strong
cytotoxic response to soluble TRAIL, whereas MF-TRAILR2-Fas
cells were highly responsive even in the absence of secondary
crosslinkers and metabolic inhibitors (Fig. S1). In the presence of
CHX and the antibody M2 used to cross-link the FLAG-tagged
ligand both cell lines showed strong cytotoxic responses at
nanomolar TRAIL concentrations (Fig. 3A), which could be fully
inhibited using the broad-range caspase inhibitor z-VAD-fmk
(data not shown). Importantly, dose response curves revealed
different sensitivities, with the TRAILR2-derived chimera showing
an approximately 100-fold higher sensitivity based on the half-
maximum effector concentration. At a concentration of 1 ng/ml
of TRAIL a near to maximum cytotoxic effect was observed in
TRAILR2-Fas positive cells, whereas TRAILR1-Fas positive MF
showed no response at all (Fig. 3A). Similar differences were
obtained also for ligand stimulation in the absence of a secondary
crosslinker (Fig. S1). Stronger cytotoxic responses of TRAILR2-
derived chimeras were paralleled by a two- to three-fold stronger
activation of caspases-8 and -3 (Fig. 3B). Overall activation kinetics
of both caspases was comparable reaching half of their maximum
activity after about two hours of ligand stimulation and their
maximum values after four hours. The higher ligand binding
affinity of the TRAILR2-derived chimera as shown in Figure 2C
might contribute to its higher apoptotic capacity paralleled by
more efficient caspase activation (Fig. 3A and B). It appears
unlikely, however, that approximately a fourfold difference in
ligand binding affinity is responsible for a sensitivity shift of almost
two orders of magnitude. Accordingly, substituting the death
domain of TRAIL death receptors with the corresponding domain
Regulation of TRAILR1 and TRAILR2 Responsiveness
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of CD95/Fas yielded chimeric death receptors with considerably
enhanced apoptotic signaling capabilities and profound differences
in their signaling strengths. As the slight difference in their ligand
binding affinities cannot explain the observed divergent signaling
strengths, the existence of additional mechanisms regulating
TRAIL receptor signal initiation is likely.
FADD is recruited to the death domains of TRAILR1-Fas
and TRAILR2-Fas chimeras
We also investigated receptor cluster formation and FADD
recruitment to the Fas-derived death domains of the receptor
chimeras by confocal microscopy visualizing colocalized FADD-
eGFP with Alexa Fluor 546-stained ligand. First clusters became
visible after about 30 minutes of ligand stimulation. We observed
similar kinetics in further cluster growth resulting in comparable
and strong cluster formation after about two hours (Fig. 3C). Thus,
cluster formation clearly preceded the observed strong activation
of caspase-8 (Fig. 3B). As in several experiments, however,
observers had the impression that TRAILR2-derived receptors
showed a somewhat faster cluster formation kinetics than their
counterparts, we quantitatively analyzed colocalization of ligand
with FADD-eGFP in MF-TRAILR1-Fas and MF-TRAILR2-Fas
cell lines, respectively, at different time points after stimulation
(Fig. S2). The results obtained are consistent with a faster cluster
formation in TRAILR2-Fas expressing cells, leading to compara-
ble clustering after longer stimulation. Yet this analysis also
revealed a high cell to cell variance of FADD and TRAIL
colocalization, thus the differences in dynamics of cluster
formation are statistically significant only for the 15 min time-
point of stimulation.
Transmembrane domain and adjacent sequences
contribute to the difference in TRAILR1 and TRALR2
signaling competence
The apoptotic activity of TRAIL receptors has been associated
with their localization in cholesterol-rich microdomains, formerly
often called lipid rafts [22,23]. Targeting of signaling molecules
into microdomains is likely to be regulated, among others, by the
transmembrane part (TM) of the receptor itself and adjacent
sequences. For TRAILR1 (cysteine residue(s) 161–163; [22]) and
the Fas molecule [24], but not TRAILR2, palmitoylation has been
demonstrated as a driving factor for partitioning within cellular
membranes. To investigate if the TMs of TRAIL receptors
influence their differential strengths in apoptosis signaling, new
chimeric molecules were generated: The extracellular ligand
binding domains were derived from TNFR1 and their cytoplasmic
signaling domains were Fas-derived. However, transmembrane
domains and the extracellular stalk regions were derived from
TRAIL receptors 1 or 2 (see schematic drawing Fig. 4A). The stalk
regions are different in length comprising about 10 amino acids
(aa) for TRAILR1 and about 34 aa for TRAILR2.
Despite the novel chimeric receptors were identical in both their
ligand binding and signaling domains significant differences were
observed. MF positive for the construct containing the TM and
stalk region of TRAILR2 (MF-TM2) showed heterogeneity at the
level of expression with an overall lower cell surface expression as
determined by flow cytometry (Fig. 4B). In spite of these reduced
levels at the cell surface MF-TM2 cells showed a significantly
higher TRAIL sensitivity. Near to maximum cytotoxic effects were
observed at TNF concentrations above 1 ng/ml, whereas MF-
TM1 cells, expressing the construct containing the TM and stalk
region of TRAILR1, were unresponsive at these ligand concen-
trations (Fig. 5A). Maximum cell death in MF-TM2 cells did not
Figure 1. Wild type mouse-derived immortalized fibroblasts, as
well as TRAILR1- and TRAILR2-positive transfectants lack
sensitivity to TRAIL-induced cell death. A. Mouse fibroblasts are
nonresponsive to the cytotoxic effects of TRAIL. Cells were treated with
FLAG-TRAIL (400 ng/ml) in the absence or presence of the crosslinking
anti-FLAG antibody M2 (2 mg/ml; 1 h 37uC) and/or 0.5 mg/ml cyclohex-
imide, as indicated. Cell viability was determined by crystal violet
staining the next day. One representative experiment (n = 3, shown are
the mean values 6 standard deviation (SD)) out of three is shown. B
and C. Immortalized mouse fibroblasts were stably transfected with
wild-type human TRAILR1 (B) or TRAILR2 (C) expression plasmids. Cell
viability was determined by crystal violet staining following 16 hour
incubation with cross-linked FLAG-TRAIL in the absence (open symbols)
or presence (closed symbols) of cycloheximide (0.5 mg/ml). One
representative experiment (n = 3, shown are the mean values 6 SD)
out of three is shown. Caspase-8 (dashed bars) and caspase-3 (black
bars) enzymatic activity following triggering of indicated receptors with
FLAG-TRAIL (previously cross-linked with anti-FLAG M2 antibody, 1 h
37uC) was quantified using specific fluorogenic substrates (Ac-IEPD-
AMC and Ac-DMQD-AMC, respectively). The insets show the expression
pattern of the human TRAIL receptors as analyzed by flow cytometry.
One representative experiment (out of three) is shown.
doi:10.1371/journal.pone.0042526.g001
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Figure 2. TRAILR1-Fas and TRAILR2-Fas chimeric receptors show ligand binding affinities comparable to the respective wild-type
TRAIL receptors. A. Schematic representation of TRAILR1-Fas and TRAILR2-Fas chimeric proteins. The cytoplasmic domain of Fas (Fas cyt), amino
acids 191–335, was fused to the C-terminus of the potential transmembrane region of TRAILR1 (amino acid 262) or TRAILR2 (amino acid 231). S = stalk
region, TM= transmembrane domain. B. Immortalized mouse fibroblasts were stably transfected with TRAILR1-Fas and TRAILR2-Fas expression
plasmids. Cell surface expression was analyzed by flow cytometry using TRAILR1- and TRAILR2-specific antibodies. Isotype controls are shown in grey.
C. Representative curves from ligand binding competition experiments on wild-type (wt) TRAILR positive cells and TRAILR-Fas chimera expressing
cells using 125I-labeled sTRAIL. IC50-values determined from ligand binding competition studies indicate differential affinities of the ligand towards
TRAILR1(-Fas) versus TRAILR2(-Fas) chimeric receptors.
doi:10.1371/journal.pone.0042526.g002
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affect more than about 50% of all cells (Fig. 5A), but this is readily
explained by the heterogeneous and on average lower expression
of the TM2 receptor chimera. In fact, MF-TM2 cells showed a
sensitivity comparable to MF-TNFR1-Fas cells, containing the
TM and stalk region of TNFR1 [21], which had been included for
comparison. Notably, strong cytotoxic responses could be initiated
by the soluble ligand TNF in the absence of a secondary
crosslinker as well as CHX. When we investigated kinetics of
caspase activation we observed in MF-TM2 cells a faster onset of
caspase enzymatic activity (Fig. 5B) as well as enzyme cleavage
(Fig. 5C) for both the initiator caspase-8 and the effector caspase-3.
MF-TRAILR1-Fas (Fig. 3B) and MF-TM1 cells (Fig. 5B) revealed
comparable activation kinetics for both caspase-8 and caspase-3,
with 50% of their activity after approximately two hours of ligand
stimulation. MF-TM2 cells, on the other hand, showed faster
caspase activation kinetics (50% of caspase activity after approx-
imately 1 hour) in comparison to both MF-TM1 and MF-
TRAILR2-Fas cells (compare Fig. 5B and Fig. 3B). Processing of
the effector caspase-3 could be detected in MF-TM2 cells as early
as after one hour of ligand stimulation. In contrast, in identically
treated MF-TM1 cells cleavage of caspase-3 was only observed
after one additional hour of TNF stimulation (Fig. 5C). These data
indicate that the TRAIL receptor-derived TM regions and/or
adjacent sequences such as the stalk regions impact on signaling
kinetics and/or strengths.
Transmembrane domains and adjacent sequences only
marginally impact ligand-binding affinities of TM1 and
TM2 chimeric receptors
TNF and TRAIL both form homotrimeric molecules capable of
binding up to three receptors [11,13]. In addition all four TRAIL
membrane receptors are able to homomultimerize in the absence
Figure 3. Differential TRAIL responsiveness, but comparable ligand/receptor cluster formation of TRAILR1-Fas and TRAILR2-Fas
receptor chimeras. A. Cytotoxic effects of TRAIL in TRAILR1-Fas and TRAILR2-Fas expressing mouse fibroblasts. MF-TRAILR1-Fas (closed squares) or
MF-TRAILR2-Fas cells (closed triangles) were treated with serial dilutions of FLAG-TRAIL (previously cross-linked with anti-FLAG M2 antibody, 1 h
37uC) in the presence of cycloheximide (0.5 mg/ml). Cell viability was determined by crystal violet staining the next day. All experimental groups
shown were performed in parallel, one representative experiment out of three is shown (performed in triplicates, shown are mean values 6 SD). B.
Caspase-8 (open symbols, dashed lines) and caspase-3 (closed symbols, solid lines) enzymatic activities following stimulation of MF-TRAILR1-Fas or
MF-TRAILR2-Fas (squares and triangles, respectively) with 100 ng/ml FLAG-TRAIL (previously cross-linked with 2 mg/ml anti-FLAG M2 antibody, 1 h
37uC) were determined using specific fluorogenic substrates (Ac-IEPD-AMC and Ac-DMQD-AMC, respectively). Data points are mean values 6 SD
calculated from three independent experiments and normalized using the highest activity value (caspase-3 activity in MF-TRAILR2-Fas after 4 hours
of stimulation). C. MF-TRAILR1-Fas and MF-TRAILR2-Fas cells were transiently transfected with a FADD-eGFP construct in the presence of 20 mM z-
VAD-fmk. The following day cells were treated with FLAG-TRAIL (300 ng/ml, previously cross-linked with 2 mg/ml mouse anti-FLAG M2 antibody, 1 h
37uC) for the indicated time periods. After fixation cells were stained with an Alexa Fluor 546-labeled anti-mouse IgG antibody and examined by
confocal laser-scanning microscopy. An optical section through the center of one representative cell for each time point is shown.
doi:10.1371/journal.pone.0042526.g003
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of ligand via the aforementioned PLAD [7,25]. It is therefore
feasible that in binding studies, performed under conditions of
reduced membrane fluidity, ligand/receptor interactions occur
with different stoichiometries resulting in distinct effective affinities
caused by avidity effects. We therefore performed equilibrium
binding studies with radioiodinated TNF revealing comparable
ligand binding affinities for the two receptor chimeras
(225617.2 nM for TM1 and 7164.3 nM for TM2; mean KD-
values 6 SD of 3 experiments each) as well as for TNFR1-Fas
(112610.8 nM; n= 3). This finding argues against major differ-
ential avidity effects. Consistently, however, MF-TM2 cells
showed an about threefold lower value for the apparent
dissociation constant compared to MF-TM1 cells (see also the
example shown in Fig. 6). Binding data had been fitted to a one
site binding hyperbola and the linearity of the respective Scatchard
analyses (Fig. 6A–C, insets) indicates good agreement with this
assumption. No indications are visible in these diagrams for the
existence of e.g. two distinct affinities. It is therefore likely that
minor conformational changes within the chimeric molecules
cause the slight affinity differences observed. In any case the
observed differences in ligand binding affinities appear too small to
explain the differential apoptotic capabilities observed. Additional
constraint(s) in TM1 and TM2 molecules must exist, most likely
located within the TM regions and/or the adjacent stalk regions,
which efficiently regulate ligand sensitivity.
TM1 and TM2 show comparable dynamics of FADD
recruitment and internalization after ligand binding
It is currently accepted that TNFR1 forms two distinct,
subsequently assembled signaling complexes of which the second-
ary, internalized complex is capable to activate caspase-8 [26,27].
In contrast, ligand activated TRAIL death receptors are believed
to signal apoptosis induction both via a membrane-associated
primarily formed DISC, and from intracellular ubiquitin-rich foci
formed after polyubiquitylation of caspase-8 [9]. We therefore
compared receptor cluster formation and internalization of the
receptor chimeras after TNF stimulation. Mouse fibroblasts
positive for TM1, TM2 or TNFR1-Fas were transiently transfect-
ed with a construct expressing human FADD-eGFP. The next day
cells were treated with Alexa Fluor 546-labeled TNF (100 ng/ml)
for the indicated time periods at 37uC, fixed and examined by
confocal laser-scanning microscopy. The examples shown in
Fig. 7A are optical sections through the center of the cells and
demonstrate comparable cluster formation of the two chimeras
comprising the TRAILR1- and TRAILR2-derived transmem-
brane parts. Additionally, they indicate significant internalization
of the chimeras in contrast to TNFR1-Fas chimeras, where
internalized clusters were hardly visible.
To study ligand/receptor complex internalization more directly,
cells were allowed to bind radioiodinated TNF at 0uC, represent-
ing conditions where receptor internalization is largely inhibited,
and were then incubated at 37uC to allow internalization. At
Figure 4. Receptor chimeras with identical ligand binding sites and intracellular signaling domains. A. Schematic representation of
TNFR1-TRAILR1-Fas (TM1), TNFR1-TRAILR2-Fas (TM2) and TNFR1-Fas chimeric proteins. TNFR1-Fas receptor was established through the fusion of the
cytoplasmic domain of Fas, amino acids 191–335, to the C-terminus of the potential transmembrane region of TNFR1 (amino acid 236). In TM1 and
TM2 receptor chimeras the stalk (S) and transmembrane (TM) regions of TNFR1 (aa 197–234) were then substituted with the corresponding regions of
TRAILR1 (amino acids 230–262) or TRAILR2 (amino acids 179–231). B. Immortalized mouse fibroblasts were stably transfected with TM1, TM2 and
TNFR1-Fas expression plasmids. Expression of the chimeras was analyzed by flow cytometry using TNFR1-specific antibodies. Percentage of positive
cells is indicated.
doi:10.1371/journal.pone.0042526.g004
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different times cells were washed at pH 7.0 to reveal total bound
radioactivity or at pH 3.0. At this acidic pH value cell surface
bound ligand is released from the receptors, whereas internalized
material remains cell-associated. TNFR1-Fas positive cells were
included as controls as they internalize ligated receptors only very
slowly (data not shown). Unspecific binding was quantified in the
presence of a 200-fold excess of unlabeled TNF. The results clearly
demonstrate that 125I-TNF had specifically bound to the cells after
the incubation period (t = 0), and could effectively be removed by
washing the cells at pH 3.0 (Fig. 7B). With increasing incubation
times at 37uC an increasing part of the radiolabeled TNF
remained cell-associated, which was interpreted as internalized
receptor chimeras. TNFR1-Fas positive control cells showed a
reduced ligand binding capacity and significant receptor internal-
ization was not observed. The decrease in total binding of these
control cells after 20 minutes is likely to be caused by ongoing
apoptosis, known to occur in TNFR1-Fas cells very rapidly [21].
Together, these results strongly suggest that the two receptor
chimeras become internalized after ligand binding at a similar
rate.
Discussion
In this study we have obtained three major results regarding the
two death receptors of the human TRAIL system. First of all, the
death domains of TRAILR1 and TRAILR2 transduce the
apoptotic signal less efficiently than the corresponding domain of
the death receptor Fas. This is also evident from the resistance to
TRAIL stimulation of most normal tissue cells but also many
tumor cells [4,28]. In accordance with these data, large T antigen
immortalized mouse fibroblasts positive for wild-type human
TRAIL receptors showed no significant cytotoxic responses upon
ligand stimulation, even in the presence of secondary ligand
crosslinkers and/or metabolic inhibitors (Fig. 1). Crosslinked
ligand, however, induced a significant activation of the transcrip-
tion factor NF-kB, as well as recruitment of huFADD-eGFP fusion
proteins into ligand/receptor complexes (data not shown),
indicating that both human receptors were functional also in a
mouse background. Furthermore, immortalized mouse fibroblasts
expressing human TNFR1-Fas receptor chimeras had been
previously shown to effectively activate the apoptotic program
[21]. Replacing the intracellular signaling parts of TRAILR1 and
TRAILR2 by the corresponding domain of Fas improved the
Figure 5. The transmembrane and stalk regions of TRAILR1 and TRAILR2 regulate apoptotic signaling. A. Cytotoxic effects of TNF in
TM1, TM2 and TNFR1-Fas expressing mouse fibroblasts. MF-TM1 (closed squares), MF-TM2 (closed triangles) or MF-TNFR1-Fas (open circles) cells were
treated with serial dilutions of TNF and cell viability was determined by crystal violet staining after 6 hours of stimulation. All experimental groups
shown were performed in parallel: one representative experiment out of three is shown. B. Caspase-8 (left panel) and caspase-3 (right panel)
enzymatic activities following triggering of TM1, TM2 and TNFR1-Fas (closed squares, closed triangles and open circles, respectively) positive cells
with TNF were determined using specific fluorogenic substrates (Ac-IEPD-AMC and Ac-DMQD-AMC, respectively). Data from a representative
experiment out of three are shown. The graphs depict normalized caspase activities (maximum relative activity = 1), as absolute activity values are
likely to be strongly influenced by the differential expression levels of the chimeric receptors. C. Western blot analyses performed using procaspase-
8- and cleaved caspase-3-specific antibodies. Cells stably expressing chimeric receptors were treated with TNF (100 ng/ml) for the indicated times,
followed by cell lysis.
doi:10.1371/journal.pone.0042526.g005
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signaling capability strongly (compare Fig. S1 and Fig. 3). The
resulting TRAILR-Fas chimeras were capable of inducing strong
apoptotic responses and revealed affinity values identical to those
of the respective wild-type receptors in ligand binding competition
studies (Fig. 2C). These results strongly suggest major differences
in the death domain signaling capabilities between the two TRAIL
receptors and Fas, although all three molecules are believed to
induce apoptosis via FADD recruitment [9,29].
The second important finding of this work is that the two
TRAILR-Fas chimeras showed significant differences in their
signaling strengths, which could neither be attributed to their
intracellular signaling parts, as these were identical, nor to
diverging ligand binding affinities, as ligand binding competition
studies revealed only a difference of a factor of approximately four.
Significant differences in their efficiency in apoptotic signaling
have been reported to occur between wild-type TRAILR1 and
TRAILR2. This aspect has gained attention in the scientific
community because many tissues co-express the two death
domain-containing TRAIL receptors and TRAIL is considered
to possess a high therapeutic potential in particular for cancer
therapy [5,6]. In some cell lines TRAILR1 dominated the
apoptotic response [14,16,17], yet in other experimental systems
the apoptotic response was strongly dependent on TRAILR2,
despite high levels of cell surface expression of TRAILR1 [15].
However, in most publications it was not taken into account that
TRAILR2, but not TRAILR1, is strongly dependent on the
membrane bound ligand form for full activation [30,31]. The anti-
FLAG M2-closslinked FLAG-tagged TRAIL used in this study
efficiently mimics the particular bioactivity of membrane bound
TRAIL, resulting in full activation of both receptors. Together, the
TRAILR2-derived chimera displays a TRAIL responsiveness
which is higher by approximately two logs as compared to the
respective TRAILR1-derived chimera, although both molecules
possess the identical Fas-derived signaling part and show ligand
binding affinities with differences of only about a factor of four.
To further minimize non-identical domains we replaced the
extracellular ligand binding domains of the receptor chimeras with
that of TNFR1. This resulted in molecules identical in both their
extracellular ligand binding parts and their intracellular signaling
domains, but different in their TM domains and the adjacent stalk
regions, i.e. the sequences connecting the TM with the cysteine
rich domains. Remarkably, comparison of these two molecules still
revealed profound differences, which is the third major result of
this study. Although showing reduced and inhomogeneous plasma
membrane expression, receptor chimera TM2, comprising TM
and stalk of TRAILR2, was still a significantly faster and stronger
activator of caspases and inducer of apoptosis than TM1 (Fig. 5).
Nevertheless, we observed comparable signaling cluster formation
(Fig. 7A) and kinetics of receptor cluster internalization in both cell
lines (Fig. 7B). Again, one obvious mechanism resulting in higher
TM2 responsiveness could result from higher affinity in ligand/
receptor interaction. However, as derived from equilibrium
binding studies with radio-iodinated TNF, binding affinities of
the receptor chimeras TM1 and TM2 were very similar showing
only an approximately threefold difference in their apparent KD-
values (Fig. 6). Moreover, the TNF concentration of 100 ng/ml
which was used in the experiments is one order higher than the
apparent KD-values of these molecules, which ensures that ligand
binding conditions are near to saturation. Under these conditions
the observed threefold difference in affinities between TM1 and
TM2 receptor chimeras should have no significant impact on the
respective signaling strengths. Accordingly, we conclude that
additional molecular mechanisms caused by distinct TM together
with the adjacent stalk regions will control kinetics of caspase
activation (Fig. 5B and C) and strength of the elicited apoptotic
signal (Fig. 5A).
Cluster formation of ligated, but also multimerisation of
unligated receptors is likely to be co-regulated by the composition
of the cell membrane being different in distinct membrane
microdomains. The TM regions of TRAILR1 and TRAILR2
Figure 6. Ligand binding affinities of receptor chimeras
differing only in their transmembrane and stalk regions. A-C.
Mouse fibroblasts expressing the indicated chimeric receptors (26105
cells per sample) were incubated with radioiodinated TNF at different
concentrations for 2 hours on ice. Cells were separated from unbound
label by centrifugation through phthalate oil and cell bound protein
was quantified. Free radioactive TNF was plotted against bound label, a
one site binding hyperbola was fitted through the data points and KD-
values were determined by using the Graphpad Prism software. Data
points represent mean values out of duplicates. The insets show
Scatchard plots of the corresponding data.
doi:10.1371/journal.pone.0042526.g006
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have comparable predicted lengths of 23 and 21 amino acids, but
the TM of TRAILR1 carries a S-palmitoylation site within the
cysteine triplet Cys261-Cys263, also present in the respective
receptor chimeras. S-palmitoylation favors localization of
TRAILR1 in cholesterol rich microdomains (‘‘lipid rafts’’) and
was shown to enhance its apoptotic activity [22], which is likely to
occur via ligand-independent enrichment/preclustering of these
molecules in membrane microdomains, allowing better respon-
siveness particularly to the soluble ligand. Another difference
between the two TM regions, which may contribute to the
formation of stable TRAILR2 homodimers, is the existence of a
GXXXG motif (aa 212–216=GIIIG), which is absent in
TRAILR1. GXXXG motifs are known to serve as dimerization
motifs of helical TMs and have been extensively studied in
glycophorin A and the Erb B receptor [32]. However, whether this
motif plays a role in TRAILR2, and therefore also in TM2
chimeras, awaits further investigation. In summary, the present
study sheds light on the molecular mechanisms behind the
observed differential apoptotic capabilities of the two TRAIL
receptors TRAILR1 and TRAILR2. Our results demonstrate that
the respective transmembrane domains together with their stalk
regions have differential regulatory properties on ligand-induced
apoptotic signaling. These results suggest that the local composi-
tion of the plasma membrane could have a regulatory function in
TRAIL death receptor signaling and would finally allow the cell to
control TRAIL sensitivity even in a spatial manner on the cell
surface.
Figure 7. Receptor chimeras with the transmembrane and stalk regions from TRAILR1 and TRAILR2 show comparable ligand-
induced receptor aggregation and internalization. A. MF-TM1, MF-TM2 and MF-TNFR1-Fas cells were transiently transfected with a construct
expressing human FADD-eGFP in the presence of 20 mM z-VAD-fmk. The following day cells were treated with Alexa Fluor 546-labeled TNF (100 ng/
ml) for the indicated time periods, fixed and examined by confocal laser-scanning microscopy. Shown are optical sections through the center of
representative cells. B. Adherent cells were incubated with 125I-TNF (30 ng/ml) for 1 h on ice, followed by incubation at 37uC and 5% CO2 for the
indicated times. Subsequently cells were washed with PBS, followed by washing with acidic buffer (pH= 3.0) to disrupt ligand/receptor interactions
on the cell surface, or again with PBS (pH=7.0). For non-specific binding (NSB) a 200-fold excess of unlabeled TNF was added during the first
incubation step. Radioactivity of the cell lysates was then quantified in a c-counter. Data points represent mean values6 SD from three independent
experiments each performed in duplicates.
doi:10.1371/journal.pone.0042526.g007
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Materials and Methods
Plasmids and polymerase chain reactions
Expression plasmids encoding the fusion proteins TRAILR1-
Fas and TRAILR2-Fas were produced by PCR cloning. The
extracellular and transmembrane domains of human TRAILR1
or TRAILR2, respectively, were amplified by PCR introducing
KpnI restriction sites at the 59 and 39 ends. This fragment was
then inserted into the previously described pBSTNFR1-Fas
plasmid [21], substituting the extracellular and transmembrane
domain of TNFR1 by the respective domains of TRAILR or
TRAILR2 and yielding the plamids pBSTRAILR1-Fas and
pBSTRAILR2-Fas.
The constructs encoding the chimeric TNFR1-TRAILR1-Fas
(TM1) and TNFR1-TRAILR2-Fas (TM2) receptors were gener-
ated by site-directed mutagenesis and molecular cloning from the
cloning vectors pBSTRAILR1-Fas, pBSTRAILR2-Fas and
pBSTNFR1-Fas. An additional BamHI endonuclease restriction
site was integrated into the plasmid pBSTRAILR1-Fas between
the membrane proximal cysteine-rich domain (CRD3) and the
stalk region. Subsequently, the fragment encoding intracellular,
transmembrane and stalk region of TRAILR1-Fas or TRAILR2-
Fas, respectively, were cloned in frame into pBSTNFR1-Fas by
(partial) digestion with BamHI. All constructs generated by PCR
were verified by sequencing and subsequently subcloned into the
expression vector pEFpgkpuroA [33] using the restriction endo-
nucleases BamHI and EcoRV (New England Biolabs Inc.),
yielding the expression constructs pEFpuroTRAILR1-Fas, pEF-
puroTRAILR2-Fas, pEFpuroTNFR1-TRAILR1-Fas and pEF-
puroTNFR1-TRAILR2-Fas. The plasmid pFADD-eGFP was a
kind gift from Michael Lenardo (National Institutes of Health,
Bethesda, MD).
Reagents
Recombinant human TNF (26107 U/mg) was kindly provided
by Knoll AG (Ludwigshafen, Germany). Flag-tagged recombinant
human TRAIL (sTRAIL) was purchased from Axxora (Lo¨rrach,
Germany). Na-125I was purchased from Hartmann Analytic
GmbH (Braunschweig, Germany). Cycloheximide was from
Sigma Aldrich Chemie GmbH (Taufkirchen, Germany). All
chemicals were of analytical grade.
Western blotting
Samples were resolved by Tris/glycine SDS-PAGE and
transferred onto nitrocellulose membrane (Whatman, Schleicher
& Schu¨ll, Dassel, Germany), which were then blocked with Roche
blocking reagent or 7.5% non-fat milk powder in 0.01% (v/v)
Tween-20/PBS for 1 hour at room temperature. Procaspase-8
(p55/p57) was detected using a-murine caspase-8 (CellSignaling
Technology Inc, Danvers, USA) antibody, for detection of cleaved
caspase-3 a-cleaved caspase-3 (CellSignaling) was used together
with a-rabbit IgG (H+L), HRP-conjugated secondary antibody
(Dianova, Hamburg, Germany).
Cell culture and cell death assays
Murine fibroblasts (MF) generated from TNFR1/TNFR2
double knockout mice and stably transfected with human
TNFR1-Fas (MF-TNFR1-Fas) have been described elsewhere
[21]. Immortalized mouse fibroblasts were grown in RPMI 1640
medium containing 2 mM L-glutamine (Invitrogen) supplemented
with 5% (v/v) heat-inactivated fetal calf serum (PAN Biotech,
Aidenbach, Germany). For cell death assays mouse fibroblasts
(16105 cells/well) were grown in 96-well plates overnight. The
next day cells were stimulated with serial dilutions of recombinant
human sTNF or sTRAIL (the latter previously crosslinked by
incubation with 2 mg/ml anti-FLAG M2 antibody for 1 hour at
37uC). Following overnight (approx. 18 hours) incubation, cells
were stained with crystal violet (20% methanol, 0.5% crystal violet)
and optical density at 550 nm was determined with an ELISA
plate reader as described [21].
Binding kinetics
Equilibrium binding studies were performed as described [21].
Briefly, TNF and TRAIL were labeled with 125I with the use of
iodobeads (Pierce, Thermo Fisher Scientific, Bonn, Germany).
Murine fibroblasts expressing the respective receptor (26105 cells)
were resuspended in PFA (PBS, 2% FCS, 0.002% sodium azide).
Cells were incubated with increasing concentrations of 125I-TNF
(0.25–12.5 ng/ml) for 2 h on ice. Non-specific binding was
determined in the presence of a 200-fold excess of unlabeled
protein. Cell-bound 125I-TNF was determined after centrifugation
of the cells through a phthalate oil mixture. For calculations of the
binding affinities a molecular mass of 51 kDa for TNF was used.
Binding competition studies using 125I-labeled TRAIL were
performed as follows. Murine fibroblasts expressing the respective
(chimeric) TRAIL receptor (46105 cells) were resuspended in PFA
and incubated with 83 ng/ml 125I-TRAIL in the presence or
absence of unlabeled recombinant human TRAIL (83–5300 ng/
ml) for 4 hours on ice. Cell bound 125I-TRAIL was then quantified
as described above. For calculation of the IC50-value a molecular
mass of 68 kDa for TRAIL was used.
Caspase activity assay
36105 cells were seeded in 6-well plates and allowed to grow
overnight. Stimulation was performed by addition of 100 ng/ml
recombinant human sTRAIL (crosslinked by pre-incubation with
2 mg/ml FLAG-specific M2 antibody) or 10 ng/ml TNF for the
indicated time periods. Subsequently, cells were harvested,
pelleted by centrifugation and the cell pellet was washed with
ice-cold PBS. Cell lysis was performed by incubation with caspase
lysis buffer (100 mM Tris-HCl pH 7.4, 200 mM NaCl, 1% NP-
40, 1 mM DTT, completeH protease inhibitor (Roche Diagnostics
GmbH, Mannheim, Germany)). Protein concentration was
determined by Bradford assay (Bio-Rad Laboratories GmbH,
Munich, Germany). For caspase-8 activity assays 20 mg, for
caspase-3 assays 2 mg of total protein were used. Cell lysates were
then incubated with caspase activity buffer (10 mM HEPES
(pH 7.4), 220 mM mannitol, 68 mM sucrose, 2 mM NaCl,
2.5 mM KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 5 mM
pyruvate, 1 mM DTT) and 40 mM caspase-3 (Ac-DMQD-AMC)
or caspase-8 (Ac-IEPD-AMC) fluorogenic substrate (Enzo Life
Science GmbH, Lo¨rrach, Germany). Fluorescence was measured
every two minutes for two hours using a Tecan infinite 200
microplate reader (Tecan Group Ltd., Ma¨nnedorf, Switzerland)
and plotted over time. Caspase activity was then calculated from
the slopes of the obtained curves.
FADD recruitment, confocal laser scanning microscopy
and image analysis
MF expressing the respective chimeric receptor (26105 cells)
were seeded on 18 mm cover slips and cultured overnight. The
following day, cells were transiently transfected with pEGFP-
FADD plasmide using LipofectamineTM 2000 (Invitrogen Life
Technologies GmbH, Darmstadt, Germany) according to the
manufacturer’s instructions. 24 hours after transfection, cells were
stimulated with antibody-crosslinked TRAIL (300 ng/ml sTRAIL
crosslinked with 2 mg/ml anti-FLAG-M2 antibody (Sigma Al-
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drich), or 100 ng/ml Alexa Fluor 546-coupled recombinant
human TNF. Subsequently, cells were washed (365 min, PBS),
fixed (4% paraformaldehyde in PBS; 15 min at RT) and blocked
(5% FCS, 0.05% Tween-20 in PBS, 30 min at RT). TRAIL
stimulated cells were additionally immunostained with 1 mg/ml
anti-mouse IgG Alexa FluorH 546 (Molecular Probes, Invitrogen).
Excess antibody and ligand was removed by washing with PBS,
and coverslips were mounted on microscope slides using Fluor-
omount GTM (SouthernBiotech, Birmingham, USA), before being
analyzed by confocal microscopy (Leica TCS confocal laser
scanning microscope (Leica Mikrosysteme Vertrieb GmbH,
Wetzlar, Germany) or Zeiss LSM710 microscope (Carl Zeiss
MicroImaging GmbH, Jena, Germany)). Colocalization analysis
was performed using the ImageJ [34] plug-in JACoP [35].
Pearson’s correlation coefficient was calculated from optical
sections of confocal z-stacks. Costes’ method for automatic
thresholding and testing of statistical significance of colocalization
was applied [36]. Statistical analysis was performed using
GraphPad Prism4.
Flow cytometry and cell sorting
For flow cytometric analysis 26105 cells, for cell sorting 36106
cells were resuspended in PBA containing the primary antibody
(anti-TNFR1 MAB225, 2.5 mg/ml; anti-TRAILR1 MAB347 or
anti-TRAILR2 MAB6311, 4 mg/ml (all from R&D Systems Inc.,
Minneapolis, USA). After incubation for 1 hour on ice cells were
washed in PBA and resuspended in PBA containing the secondary
antibody (FITC-conjugated goat anti-mouse-IgG+IgM (H+L);
Dianova) at a final concentration of 7.5 mg/ml. After 45 min of
incubation cells were washed again and resuspended in 400 ml of
PBA. Cells were analyzed using Beckman Coulter Cytomics FC
500, or sorted using Becton Dickinson FACS Vantage SE with
FACSDiVa. For sorting, 36104 positive cells were collected in 5 ml
of RPMI 1640+5% FCS containing 100 U/ml penicillin and
100 mg/ml streptomycin. Immediately after sorting cells were
transferred into 6-well plates and cultured at 37uC and 5% CO2.
Analysis of receptor internalization
26105 cells were seeded in 6-well plates and allowed to grow
over night. The next day, plates were placed on ice, culture
medium was removed and replaced with 1 ml RPMI+5% FCS
containing 30 ng/ml 125I-TNF. To quantify nonspecific binding in
addition a 200-fold excess of unlabeled TNF was present in the
respective groups. After incubation on ice for 1 h plates were
transferred to an incubator (37uC, 5% CO2) and incubated for
different time periods. The plates were washed with phosphate-
buffered saline (pH 7.0) followed either by an acid wash (50 mM
glycine, 125 mM NaCl, pH 3.0) to disrupt accessible ligand-
receptor interactions, or again with PBS. Cells were again washed
twice with PBS, lysed by addition of 1 ml 1 M NaOH and
radioactivity of the lysates was quantified using a c-counter (LB
2100, Berthold, Bad Wildbad, Germany). Experiments were
performed in duplicates. Radioactivity in the cell lysates of
pH 3-treated groups corrected for unspecific binding was inter-
preted to represent internalized material, whereas the respective
pH 7-treated group reveals cell surface bound plus internalized
material.
Supporting Information
Figure S1 Cellular responses of MF-TRAILR1-Fas and
MF-TRAILR2-Fas cells to TRAIL stimulation in absence
of a secondary ligand crosslinkiner. MF-TRAILR1-Fas
cells (A) and MF-TRAILR2-Fas cells (B) were treated with serial
dilutions of recombinant human FLAG-TRAIL (300–0.046 ng/
ml; without crosslinking secondary antibodies) in presence
(triangles) or absence (squares) of 0.5 mg/ml of the protein
synthesis inhibitor cycloheximide or left untreated. Cell viability
was determined by crystal violet staining after 18 h of stimulation.
All experiments were performed in parallel: one representative
experiment out of three is shown (mean values of triplicates6 SD).
TRAILR1-Fas expressing cells show significant cytotoxic response
only when co-stimulated with cycloheximide, whereas TRAILR2-
Fas positive cells are responsive to TRAIL in the absence of
additional stimuli.
(EPS)
Figure S2 Kinetics of FADD-eGFP recruitment and
cluster formation in MF-TRAILR1-Fas and MF-
TRAILR2-Fas cells. Colocalization of FADD-eGFP and Alexa
Fluor 546-stained TRAIL was quantified using the ImageJ plug-in
JACoP. Pearson’s correlation coefficient (rp) was calculated from at
least 15 cells per time point from three independent experiments
(shown are mean values 6 SD). For the unstimulated controls
(t = 0 min) cells were incubated with FLAG-TRAIL (300 ng/ml,
previously cross-linked with 2 mg/ml mouse anti-Flag M2
antibody, 1 h 37uC) for 15 min at 0uC to allow binding of the
ligand under conditions of highly reduced membrane fluidity.
Cells expressing TRAILR2-Fas (grey bars) show higher colocaliza-
tion after 15 min stimulation (p,0.05, non-parametric Mann-
Whitney U-test) compared to TRAILR1-Fas expressing MFs
(white bars). Stimulation for 30 min or longer showed no
significant difference, although the tendency for an enhanced
FADD recruitment was clearly visible also after 30 and 60 min of
stimulation in TRAILR2-Fas cells.
(EPS)
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